Management and Novel Adjuncts of Necrotizing Soft Tissue Infections.
Surg Infect (Larchmt)
; 18(3): 250-272, 2017 Apr.
Article
en En
| MEDLINE
| ID: mdl-28375805
Necrotizing soft tissue infections (NSTI) have been recognized for millennia and continue to impose considerable burden on both patient and society in terms of morbidity, death, and the allocation of resources. With improvements in the delivery of critical care, outcomes have improved, although disease-specific therapies are lacking. The basic principles of early diagnosis, of prompt and broad antimicrobial therapy, and of aggressive debridement have remained unchanged. Clearly novel and new therapeutics are needed to combat this persistently lethal disease. This review emphasizes the pillars of NSTI management and then summarizes the contemporary evidence supporting the incorporation of novel adjuncts to the pharmacologic and operative foundations of managing this disease.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fascitis Necrotizante
/
Desbridamiento
/
Antiinfecciosos
Tipo de estudio:
Screening_studies
Límite:
Humans
Idioma:
En
Revista:
Surg Infect (Larchmt)
Asunto de la revista:
BACTERIOLOGIA
Año:
2017
Tipo del documento:
Article
Pais de publicación:
Estados Unidos